AMPG vs ASML

AMPG's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a remarkable 115% YoY revenue growth and a recent positive earnings surprise, the company operates at a significant loss with negative ROE (-27.13%) and ROA (-13.23%), and its gross margin (23.07%) is insufficient to offset deep operating and net losses. The stock trades at a premium valuation (P/S of 2.86, forward P/E of 4.74) despite negative profitability, suggesting high growth expectations that may not be sustainable. Analysts' target price of $9.00 reflects optimism, but with only one analyst covering the stock and no insider buying, conviction remains low.

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.